Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists

SEEL - Seelos Therapeutics Inc Stock Price, Fair Value and News

00
Delayed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

SEEL Price Action

Last 7 days

8.3%

Last 30 days

14.7%

Last 90 days

-83.9%

Trailing 12 Months

-99.8%

SEEL Stock Price

SEEL RSI Chart

MayJunJulAugSepOctNovDec20250102030405060708090

SEEL Valuation

Price/Earnings (Trailing)

0.02

Price/Sales (Trailing)

0.05

EV/EBITDA

0.01

Price/Free Cashflow

-0.01

MarketCap/EBT

0

SEEL Price/Sales (Trailing)

202220232024202505K10K15K20K25K30K35K

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

SEEL Fundamentals

SEEL Revenue

Revenue (TTM)

2.0M

Rev. Growth (Yr)

11.9%

Rev. Growth (Qtr)

-35.06%

2010201220142016201820202022202402M4M6M8M10M

SEEL Earnings

Earnings (TTM)

4.1M

Earnings Growth (Yr)

105.8%

Earnings Growth (Qtr)

164.19%

20102012201420162018202020222024-80M-60M-40M-20M0

SEEL Profitability

EBT Margin

-1108.06%

Return on Equity

51.92%

Return on Assets

171.82%

Free Cashflow Yield

-14.3K%

SEEL Investor Care

Shares Dilution (1Y)

40.31%

Diluted EPS (TTM)

366.56

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
2010201220142016201820202022202402M4M6M8M10M
Net sales
YearQ1Q2Q3Q4
20242.0M2.0M00
2023910.0K1.2M1.6M2.2M
2022120.0K0127.0K128.0K
202137.0K59.0K94.0K113.0K
2020392.0K409.0K38.0K45.0K
20194.4M3.1M1.7M375.0K
20165.0M5.0M8.0M5.8M
20159.7M4.7M4.1M4.8M
201407.0M7.7M9.6M
20138.2M9.4M4.5M2.5M
20124.7M5.8M6.9M7.9M
20115.2M5.3M5.0M3.6M
201003.6M4.3M5.0M
20090003.0M
Get all data in R, Python etc through our Historical Stock Data APIs

About Seelos Therapeutics Inc

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.
 CEO
 WEBSITEhttps://seelostherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES16

Seelos Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Seelos Therapeutics Inc? What does SEEL stand for in stocks?

SEEL is the stock ticker symbol of Seelos Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Seelos Therapeutics Inc (SEEL)?

As of Wed Jan 29 2025, market cap of Seelos Therapeutics Inc is 0. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SEEL stock?

You can check SEEL's fair value in chart for subscribers.

Is Seelos Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether SEEL is over valued or under valued. Whether Seelos Therapeutics Inc is cheap or expensive depends on the assumptions which impact Seelos Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SEEL.

What is Seelos Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Jan 29 2025, SEEL's PE ratio (Price to Earnings) is 0.02 and Price to Sales (PS) ratio is 0.05. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SEEL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Seelos Therapeutics Inc's stock?

In the past 10 years, Seelos Therapeutics Inc has provided -0.78 (multiply by 100 for percentage) rate of return.